Netris Pharma SAS has entered into a scientific collaboration agreement with Orano SA and the Centre Léon Bérard (CLB) to develop novel antibody-radio conjugates for the treatment of cancer.

Avicanna Inc. has expanded its research in the field of epilepsy through a new collaboration with the University of Toronto to explore the efficacy of Avicanna's proprietary formulations in preclinical models of epilepsy.

Coave Therapeutics SA has entered into a collaboration with the Institute of Neurodegenerative Diseases (IMN), a joint research unit associating the University of Bordeaux and the French National Centre of Scientific Research (CNRS), to develop gene therapy programs targeting protein degradation in neurodegenerative disorders.

Nanotics LLC has established a research collaboration with Mass General Cancer Center (MGCC), a program of Massachusetts General Hospital (MGH), to develop Nanots that target the soluble forms of tumor necrosis factor (TNF) receptors (sTNF-Rs).

Hansoh Pharmaceutical's Hansoh (Shanghai) Healthtech subsidiary has entered into an exclusive licensing and codevelopment agreement with the Global Health Drug Discovery Institute (GHDDI; Beijing Huayi Health Drug Discovery Institute) for exclusive worldwide rights to develop, manufacture and commercialize GDI-4405, an oral small-molecule SARS-CoV-2 3CL protease inhibitor.

Jemincare and its wholly owned subsidiary Shanghai Jemincare Pharmaceutical have signed an exclusive worldwide license agreement with Roche and Genentech for the development and commercialization of the androgen receptor degrader JMKX-002992.

Merck & Co. is to collaborate with Orna Therapeutics on discovery, development and commercialization in multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology.